Khan Safi U, Khan Muhammad U, Rahman Hammad, Khan Muhammad Shahzeb, Riaz Haris, Novak Matthew, Opoku-Asare Isaac, Kaluski Edo
Guthrie Health System/Robert Packer Hospital, Sayre, PA, USA.
Guthrie Health System/Robert Packer Hospital, Sayre, PA, USA.
Cardiovasc Revasc Med. 2019 Jan;20(1):29-37. doi: 10.1016/j.carrev.2018.06.005. Epub 2018 Jun 12.
The optimal preventive strategy for contrast induced acute kidney injury (CIAKI) in patients undergoing cardiac catheterization remains uncertain.
We conducted Bayesian network meta-analysis (NMA) to compare different preventive strategies for CIAKI in these cohorts.
Forty-nine randomized controlled trials were extracted using MEDLINE, EMBASE and CENTRAL data bases (inception-1st December 2017). We calculated median of the odds ratio (OR) with the corresponding 95% credible interval (CrI). The ranking probability of each treatment was based on SUCRA (surface under the cumulative ranking curve).
In NMA of 28,063 patients [normal saline (NS: 9716 patients), sodium bicarbonate (NaHCO3: 4484 patients), statin (2542 patients), N-acetylcysteine (NAC: 3006 patients), NAC + NaHCO3 (774 patients), NS + NAC (3807 patients), NS + NaHCO3 (135 patients) and placebo (3599 patients)], statins reduced the relative risk of CIAKI compared with NS (OR: 0.50; 95% CrI, 0.25-0.99), and placebo (OR: 0.44; 95% CrI, 0.24-0.83). Subgroup analyses showed that in patients receiving low osmolar contrast, statins reduced the relative risk of CIAKI by 58% versus NS, and 51% versus placebo. There were no significant differences across all the treatments in terms of risk of hemodialysis or all-cause mortality. Statins had the highest probability for reducing the risk of CIAKI (SUCRA, 0.86), risk of hemodialysis (SUCRA, 0.88) and all-cause mortality (SUCRA, 0.81).
Statins were the superior preventive strategy for reducing the risk of CIAKI compared with NS alone and placebo.
对于接受心脏导管插入术的患者,对比剂诱导的急性肾损伤(CIAKI)的最佳预防策略仍不确定。
我们进行了贝叶斯网络荟萃分析(NMA),以比较这些队列中CIAKI的不同预防策略。
使用MEDLINE、EMBASE和CENTRAL数据库(起始时间至2017年12月1日)提取了49项随机对照试验。我们计算了比值比(OR)的中位数及其相应的95%可信区间(CrI)。每种治疗的排序概率基于累积排序曲线下面积(SUCRA)。
在对28063例患者的NMA中[生理盐水(NS:9716例患者)、碳酸氢钠(NaHCO3:4484例患者)、他汀类药物(2542例患者)、N-乙酰半胱氨酸(NAC:3006例患者)、NAC+NaHCO3(774例患者)、NS+NAC(3807例患者)、NS+NaHCO3(135例患者)和安慰剂(3599例患者)],与NS相比,他汀类药物降低了CIAKI的相对风险(OR:0.50;95%CrI,0.25 - 0.99),与安慰剂相比(OR:0.44;95%CrI,0.24 - 0.83)。亚组分析显示,在接受低渗对比剂的患者中,与NS相比,他汀类药物使CIAKI的相对风险降低了58%,与安慰剂相比降低了51%。在血液透析风险或全因死亡率方面,所有治疗之间均无显著差异。他汀类药物降低CIAKI风险(SUCRA,0.86)、血液透析风险(SUCRA,0.88)和全因死亡率(SUCRA,0.81)的概率最高。
与单独使用NS和安慰剂相比,他汀类药物是降低CIAKI风险的更优预防策略。